Arpida

Arpida AG
legal form	Corporation
founding	1997
resolution	2009
Reason for dissolution	fusion
Seat	Reinach , Switzerland
management	Jürgen Raths ( CEO ) André Lamotte ( Chairman of the Board of Directors )
Number of employees	78
sales	0.4 million CHF
Branch	Pharmaceutical research
As of December 31, 2008

The Arpida AG , based in Basel-scenic Reinach was a Swiss biopharmaceutical undertakings incinerating or the antimicrobial agents researched and developed. Founded in 1997, employed up to 90 staff (2006) and was from 2005 on the Swiss Exchange SIX Swiss Exchange listed . It ceased operations in 2009.

Field of activity

The research - and development activities Arpida focused on antimicrobial agents that the growing problem of microbial resistance should be overcome. The company had a pipeline of various product candidates.

One of the most advanced projects was the antibacterial agent Iclaprim , which was submitted to the US and European drug agencies for approval testing. Iclaprim was an intravenous antibiotic. It should be used against severe infections, including those caused by methicillin- resistant Staphylococcus aureus , that require hospital treatment.

In addition to its antibiotic programs, Arpida also had an antifungal agent to combat fungal infections in phase III clinical development for the treatment of nail fungus .

After a failed Phase III study with Iclaprim, Arpida was forced to stop its research and development work and lay off all employees. The Iclaprim activities were sold to Acino Holding AG and the remaining company shell was merged with the Basel biotechnology company Evolva . At that time Evolva had approximately 75 employees in locations in Switzerland, Denmark, the United States and India.

Web links

• Historical Arpida website ( Memento of December 11, 2009 in the Internet Archive )

Individual evidence

1. ↑ ^{a b} Arpida Annual Report 2008 ( Memento from May 17, 2014 in the Internet Archive ) (English), www.evolva.com, accessed on May 15, 2014.